Company Overview

Restart Life Sciences Corp. is a biotechnology company focused on the development and commercialization of novel therapeutic candidates derived from psilocybin, a psychedelic compound, for the treatment of neurological and neuropsychiatric disorders. The company operates within the biotechnology and life sciences industries, with an emphasis on drug discovery, preclinical research, and intellectual property development related to central nervous system (CNS) conditions. Its core strategy centers on identifying proprietary psilocybin-based drug candidates and advancing them through early-stage development for potential clinical application.

The company’s primary revenue drivers are not yet based on commercial product sales, as Restart Life Sciences remains in the development stage. Instead, its value proposition is tied to its intellectual property portfolio, research programs, and potential future licensing or partnership opportunities. Restart Life Sciences evolved from a broader life sciences focus into a specialized psychedelic medicine company as interest and regulatory openness toward psychedelic-assisted therapies increased in North America.

Business Operations

Restart Life Sciences’ operations are primarily organized around drug discovery and preclinical development, with a focus on psilocybin synthesis, formulation, and delivery methods aimed at improving therapeutic outcomes. The company does not report diversified operating segments; rather, its activities are concentrated on advancing a limited number of lead programs targeting neurological inflammation, traumatic brain injury, and other CNS-related conditions.

Operationally, the company relies on a combination of internal research management and third-party laboratories for scientific validation and preclinical testing. Based on publicly available disclosures, Restart Life Sciences does not currently operate revenue-generating subsidiaries or large-scale manufacturing assets, and its activities are predominantly domestic. Information regarding material joint ventures or long-term strategic partnerships is limited, and available public sources do not consistently confirm any revenue-producing collaborations.

Strategic Position & Investments

Restart Life Sciences’ strategic direction is centered on establishing a defensible intellectual property position in psilocybin-based therapeutics and positioning itself for future clinical development or strategic transactions. Growth initiatives have focused on patent filings, research data generation, and regulatory groundwork necessary for advancing psychedelic compounds within established pharmaceutical frameworks.

The company has disclosed intentions to pursue acquisitions or in-licensing opportunities that complement its core psilocybin research; however, publicly available filings and market disclosures do not consistently verify the completion of any material acquisitions. Information regarding notable subsidiaries, portfolio companies, or significant capital investments remains limited, and in several cases, data is inconclusive based on available public sources.

Geographic Footprint

Restart Life Sciences is headquartered in North America, with its corporate and administrative functions primarily based in Canada. Its operational footprint is limited, reflecting its early-stage development status, and there is no verified evidence of significant physical operations outside this region.

While the company positions its research and intellectual property for potential global application, particularly in jurisdictions exploring regulatory pathways for psychedelic therapies, there is limited publicly verified information confirming active international operations or investments. As such, its current geographic influence appears largely domestic, with an aspirational international outlook.

Leadership & Governance

Restart Life Sciences is led by a small executive team responsible for corporate strategy, scientific direction, and capital markets engagement. Governance is overseen by a board of directors with experience in biotechnology, capital markets, and early-stage company development. The leadership philosophy emphasizes scientific credibility, capital efficiency, and long-term value creation through intellectual property development.

Key executives include:

• Hugh Rogers – Chief Executive Officer
• John Rizzo – Chief Financial Officer
• David Ryan – Director

Public disclosures provide limited detail regarding broader executive management or independent board committee structures. Where additional leadership roles are referenced across market sources, the information is inconsistent, and further verification is inconclusive based on available public sources.